In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
386 News Items found
An MSK scientists works in the lab
MSK Research Highlights, August 13, 2024

New MSK research found patients with non-small cell lung cancer brain metastases may benefit from up-front stereotactic radiosurgery; identified a connection between antibiotic use and autoimmune diseases; and uncovered a previously unknown structural role for messenger RNAs in the cytoplasm of cells.
(Left to right) Sascha Roth, Luis Diaz, Imtiaz Hussain, Andrea Cercek, Avery Holmes, and Nisha Varughese.
Feature
Top Cancer Treatment Advances at MSK in 2022

Doctors at Memorial Sloan Kettering Cancer Center (MSK) pioneered advances in many types of cancer treatment for patients in 2022. Here are some of the most important developments.
Dr. Alexander Drilon
FDA Grants Accelerated Approval to Repotrectinib for Cancers with NTRK Fusions 

The FDA has approved the targeted drug repotrectinib for patients 12 and older with tumors that carry gene changes called NTRK fusions. The trial that resulted in the approval was led by MSK investigators.
Dr. Bob Li
First Drug Targeting HER2-Mutant Non-Small Cell Lung Cancer Approved by FDA

The FDA has approved the drug trastuzumab deruxtecan for the treatment of advanced non-small cell lung cancer driven by mutant HER2. An MSK-led study published in September 2021 contributed to the drug's approval.
MSK patient Michael Simien poses with his bicycle in front of a fountain in New York City
This Remarkable MSK Patient Is Living With Two Kinds of Stage 4 Cancer

Learn how it's possible to stay active even with two types of advanced cancer — lung cancer and mantle cell lymphoma — thanks to innovative treatments at MSK.
Yi-Long Wu, President of CTONG, and Sir Murray Brennan, MSK’s Senior Vice President of International Programs; center: Honorable Kevin Rudd, 26th Prime Minister of Australia and 8th President and CEO of Asia Society; right (top to bottom): Lisa DeAngelis, MSK’s Physician-in-Chief and Chief Medical Officer, and Bob Li, MSK’s Physician Ambassador to China and Asia-Pacific
In the News
Memorial Sloan Kettering and the Chinese Thoracic Oncology Group Strengthen International Collaboration During Annual Symposium

The initiative lays the groundwork for speedier cancer drug approvals in both the United States and China.
A researcher pipettes in the lab
MSK Research Highlights, June 25, 2024

New MSK research helped develop a machine-learning tool to help find cancer cells that remain after surgery; led to FDA approval for CAR T cell therapy against mantle cell lymphoma; tested a liquid biopsy approach that shows promise in detecting lung cancer; found checkpoint inhibitors were effective against endometrial and ovarian cancers with DNA-repair deficiency; and shed new light on mTOR's role in metabolic enzyme degradation.
a lab coat hangs in an MSK lab
MSK Research Highlights, November 6, 2024

New MSK research marks a potential advance against RAS-driven cancers; breaks down data silos to better predict cancer outcomes with the help of artificial intelligence (AI); identifies two enzymes vital for maintaining brain health; uncovers how changes to “helper” proteins drive cancer cell survival; develops a new model for investigating lung cancer metastasis; and uses AI to improve outcome predictions in sarcoma.
Dr. Bob Li
Medical Oncologist Bob Li Featured in the Presidential Symposium at the 2020 World Conference on Lung Cancer

Dr. Bob Li will present registrational phase II data from the first-ever trial of a drug that blocks cancer gene KRAS.
Pictured: Cancer cell on blood vessel
In the Lab
Holding On and Hiding Out: How Cancer Cells Spread to the Brain and Thrive

Researchers have gained new understanding of how tumors metastasize by studying the behavior of exceptional breast and lung cancer cells that are capable of entering the brain and surviving there.